Home Cart Sign in  
Chemical Structure| 119478-56-7 Chemical Structure| 119478-56-7

Structure of Meropenem Trihydrate
CAS No.: 119478-56-7

Chemical Structure| 119478-56-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Meropenem Trihydrate is a broad-spectrum antibiotic used to treat a variety of bacterial infections active against Gram-positive and Gram-negative bacteria.

Synonyms: SM 7338 trihydrate; Meropenem (hydrate); SM-7338

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Meropenem Trihydrate

CAS No. :119478-56-7
Formula : C17H31N3O8S
M.W : 437.51
SMILES Code : O=C(C(N12)=C(S[C@@H]3CN[C@H](C(N(C)C)=O)C3)[C@H](C)[C@]2([H])[C@@H]([C@H](O)C)C1=O)O.[H]O[H].[H]O[H].[H]O[H]
Synonyms :
SM 7338 trihydrate; Meropenem (hydrate); SM-7338
MDL No. :MFCD08600005

Safety of Meropenem Trihydrate

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H317-H334
Precautionary Statements:P261-P272-P280-P284-P302+P352-P304+P340-P333+P313-P342+P311-P362+P364-P501

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Red blood cells 1000 mg/mL Evaluate hemolytic activity, results showed no hemolysis even at 1000 mg/mL concentration. Acta Pharm Sin B. 2021 Jan;11(1):203-221
NDM-1-negative E. coli 0.03 µg mL−1 24 hours Evaluate the antibacterial activity of Meropenem against NDM-1-negative E. coli, showing an MIC of 0.03 µg mL−1 Nat Commun. 2018 Jan 30;9(1):439
NDM-1-positive E. coli 16 µg mL−1 24 hours Evaluate the antibacterial activity of Meropenem against NDM-1-positive E. coli, showing an MIC of 16 µg mL−1 Nat Commun. 2018 Jan 30;9(1):439

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice Sepsis mouse model Subcutaneous injection 10 mg/kg (MEM), 30 mg/kg (19bh) Single dose, monitored for 96 hours Evaluate the in vivo efficacy of compound 19bh combined with MEM, results showed that the combination treatment was markedly effective in treating infections caused by NDM-1 positive strain and prolonged the survival time of sepsis mice. Acta Pharm Sin B. 2021 Jan;11(1):203-221
BALB/c mice Peritonitis model Intraperitoneal injection 5 mg/kg Twice daily until the endpoint of the experiment Evaluate the efficacy of Meropenem and CBS combination therapy in mice infected with NDM-1-positive bacteria, showing a significant increase in survival rate Nat Commun. 2018 Jan 30;9(1):439
Mice Allogeneic hematopoietic stem cell transplantation (allo-HSCT) model Oral (drinking water) 0.625 g/L (drinking water) Daily, from day 3 to day 15 post-transplantation To study the effect of meropenem on GVHD, finding that meropenem treatment aggravates colonic GVHD, leading to thinning of the colonic mucus layer and bacterial translocation Cell. 2022 Sep 29;185(20):3705-3719. e14
Mice Escherichia coli sepsis model Intravenous injection 10 mg/kg Single dose at 2 or 8 hours post-infection To evaluate the effect of Meropenem on the sepsis model, results showed that Meropenem significantly reduced bacterial load in heart, lung, and kidney, but had less effect on spleen and liver. Nat Commun. 2023 Jun 17;14(1):3603
C57BL/6 mice Pneumonia and bacteremia models Meropenem subcutaneously, mAbs intravenously Meropenem: 7.5 mg/kg (O1 strain) or 50 mg/kg (O2 strain); mAbs: 1 mg/kg (KPE33) or 0.2 mg/kg (KPN42) Administered 1 hour post-infection, survival monitored daily Evaluate synergistic therapeutic effect of anti-O antigen mAbs with meropenem, showing combination therapy significantly improved survival against resistant strains. Nat Commun. 2017 Dec 8;8(1):1991
Mice Tissue cage implant infection model Intraperitoneal injection 100 mg/kg Once daily for 10 days Evaluate the efficacy of Meropenem combined with phage Paride in chronic infections. Results showed that the combination significantly reduced bacterial loads. Nat Commun. 2024 Jan 2;15(1):175
Swiss Webster mice Gestational sepsis model Subcutaneous injection 10 mg/kg After 5 h, 24 h, 48 h, and 72 h To evaluate the therapeutic effect of meropenem on gestational sepsis and its impact on offspring. Results showed that meropenem treatment alleviated sepsis symptoms, but offspring still exhibited abnormalities in neurodevelopment and behavior. J Neuroinflammation. 2021 Feb 25;18(1):60
Mice Antibiotic-induced gut dysbiosis model Oral gavage 21.6 mg Twice daily (days 0-6), once daily (days 7-11), for 11 days To investigate the effects of antibiotic-induced gut dysbiosis on cognitive function. Results showed that meropenem, in combination with other antibiotics, significantly altered gut microbiota composition, reduced bacterial metabolite levels in the colon and plasma, and impaired novel object recognition memory in mice. Brain Behav Immun. 2016 Aug;56:140-55
Mice Pseudomonas aeruginosa keratitis model Topical administration 0.5 mg/mL Every 8 hours for 72 hours To evaluate the efficacy of meropenem in combination with LasB inhibitor (R)-30 for treating Pseudomonas aeruginosa keratitis. Results showed that the combination significantly reduced bacterial load and clinical symptoms, outperforming meropenem alone. Adv Sci (Weinh). 2025 Apr;12(14):e2411807

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01551394 Sepsis Phase 3 Completed - Italy ... More >> Ursula TRAFOJER Padova, Italy, 35128 Less <<
NCT01554124 Meningitis Phase 1 Phase 2 Completed - United Kingdom ... More >> HEATH, Paul London, Cranmer Terrace, United Kingdom, SW17 ORE Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.29mL

0.46mL

0.23mL

11.43mL

2.29mL

1.14mL

22.86mL

4.57mL

2.29mL

References

 

Historical Records

Categories